Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27717791 | 1.00 | NFE2L2 (0.40) | NFE2L2PTGES2HTR2AHTR2CABCG2 | |
| SCHEMBL27738977 | 0.88 | PTGES2 (0.39) | NFE2L2PTGES2ABCG2KCNH2RAB9A | |
| SCHEMBL4620139 | 0.88 | PTGES2 (0.39) | NFE2L2PTGES2ABCG2KCNH2RAB9A | |
| SCHEMBL27738961 | 0.86 | NFE2L2 (0.40) | NFE2L2PTGES2ABCG2KCNH2RAB9A | |
| SCHEMBL5419662 | 0.86 | NFE2L2 (0.40) | NFE2L2PTGES2ABCG2KCNH2RAB9A | |
| SCHEMBL5409079 | 0.84 | PTGES2 (0.50) | NFE2L2PTGES2KDM4E | |
| SCHEMBL27717772 | 0.84 | PTGES2 (0.41) | NFE2L2PTGES2HTR2AHTR2CABCG2 | |
| SCHEMBL5404081 | 0.84 | PTGES2 (0.41) | NFE2L2PTGES2HTR2AHTR2CABCG2 | |
| SCHEMBL4619057 | 0.83 | CA12 (0.48) | NFE2L2PTGES2ABCG2KCNH2RAB9A | |
| SCHEMBL5426631 | 0.83 | ALDH1A1 (0.44) | PTGES2HTR2AHTR2CKCNH2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | claimed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | claimed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | claimed |
| CN-101268042-A | Styryl sulfonamides, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| US-7208526-B2 | For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270874-A1 | Styrylsulfonamides | HOFFMANN-LA ROCHE INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270874-A1 | Styrylsulfonamides | STS, SULT1E1, BRCA1 | NFE2L2 1842/4885PTGES2 3551/4885HTR2A 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.